Fabrazyme confirmatory results
This article was originally published in Pharmaceutical Approvals Monthly
Genzyme plans to submit results of the principal confirmatory Phase IV study for its Fabry disease therapy Fabrazyme "for labeling purposes early next year," the firm says Sept. 9. A summary study report will be submitted in September. Fabrazyme (agalsidase beta) received accelerated approval for the orphan disease April 24, 2003. According to a preliminary analysis, of the 82 patients enrolled in the double-blind study, those receiving Fabrazyme were 53% less likely than placebo to experience a precursor disease event (p=0.058). Data will be presented at medical meetings in October, including the American Society of Nephrology. The firm is conducting another Phase IV verification study, due to FDA by April 2006...
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.